Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels
Background: There have been concerns about the cardiovascular safety of omalizumab. Objectives: In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated. Materials and methods: In a pilot study described below we ex...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 Jul 2013
|
| In: |
Expert opinion on biological therapy
Year: 2013, Jahrgang: 13, Heft: 9, Pages: 1335-1341 |
| ISSN: | 1744-7682 |
| DOI: | 10.1517/14712598.2013.819338 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14712598.2013.819338
|
| Verfasserangaben: | Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G. Strauss, Felix Herth |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1764227867 | ||
| 003 | DE-627 | ||
| 005 | 20230426140748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210723s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14712598.2013.819338 |2 doi | |
| 035 | |a (DE-627)1764227867 | ||
| 035 | |a (DE-599)KXP1764227867 | ||
| 035 | |a (OCoLC)1341419723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Yalcin, Arzu Didem |e VerfasserIn |0 (DE-588)1217820205 |0 (DE-627)1733243291 |4 aut | |
| 245 | 1 | 0 | |a Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels |c Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G. Strauss, Felix Herth |
| 246 | 3 | 3 | |a Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels |
| 264 | 1 | |c 24 Jul 2013 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.07.2021 | ||
| 520 | |a Background: There have been concerns about the cardiovascular safety of omalizumab. Objectives: In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated. Materials and methods: In a pilot study described below we examined the levels of serum eosinophil cationic peptid (ECP), CD200, d-dimer, 25-hydroxyvitamin D (25(OH)D), CXCL8 and IL-1β in asthma patients treated with anti-IgE therapy, to explore their relationship with disease activity, and the impact of anti-IgE therapy impact on those levels. Exercise stress testing and blood samples were taken at all follow up visits from the time of first diagnosis and after 20 months of treatment during the disease remission. Results: Fractional exhaled nitric oxide concentrations and serum levels of sTRAIL, sCD200, D-dimer, ECP, total IgE, IL-1β and Hs-CRP were decreased while CXCL8, 25(OH)D were increased after starting the treatment of anti-IgE. Our first case of a patient, who had both protein C and S deficiency and hence a high risk for thromboembolism, documents for the first time the safety of omalizumab for asthmatic patients with concurrent risk factors contributing to arteriothrombotic events. Conclusion: Omalizumab might be used carefully in patients with cardiovascular diseases. | ||
| 650 | 4 | |a 25-hydroxyvitamin D | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a cardiovascular risk | |
| 650 | 4 | |a CXCL8 | |
| 650 | 4 | |a IL-1β | |
| 650 | 4 | |a omalizumab | |
| 650 | 4 | |a protein C and S deficiency | |
| 650 | 4 | |a sCD200 | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d Abingdon : Taylor & Francis Group, 2001 |g 13(2013), 9, Seite 1335-1341 |h Online-Ressource |w (DE-627)355985446 |w (DE-600)2091082-4 |w (DE-576)302969578 |x 1744-7682 |7 nnas |a Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels |
| 773 | 1 | 8 | |g volume:13 |g year:2013 |g number:9 |g pages:1335-1341 |g extent:7 |a Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels |
| 856 | 4 | 0 | |u https://doi.org/10.1517/14712598.2013.819338 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210723 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 50000 |e 50000PH1016095236 |k 0/50000/ |p 5 |y j | ||
| 999 | |a KXP-PPN1764227867 |e 3957105595 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G. Strauss, Felix Herth"]},"origin":[{"dateIssuedDisp":"24 Jul 2013","dateIssuedKey":"2013"}],"recId":"1764227867","person":[{"role":"aut","given":"Arzu Didem","display":"Yalcin, Arzu Didem","family":"Yalcin"},{"role":"aut","display":"Herth, Felix","given":"Felix","family":"Herth"}],"titleAlt":[{"title":"Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels"}],"title":[{"title":"Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels","title_sort":"Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels"}],"language":["eng"],"id":{"eki":["1764227867"],"doi":["10.1517/14712598.2013.819338"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"7 S."}],"note":["Gesehen am 23.07.2021"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"1335-1341","year":"2013","text":"13(2013), 9, Seite 1335-1341","volume":"13","issue":"9","extent":"7"},"id":{"zdb":["2091082-4"],"issn":["1744-7682"],"eki":["355985446"]},"note":["Gesehen am 08.09.15"],"origin":[{"publisherPlace":"Abingdon ; London ; London","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisher":"Taylor & Francis Group ; Ashley ; Informa Healthcare"}],"title":[{"title":"Expert opinion on biological therapy","title_sort":"Expert opinion on biological therapy"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2001 -"],"recId":"355985446","disp":"Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levelsExpert opinion on biological therapy","language":["eng"]}]} | ||
| SRT | |a YALCINARZUOMALIZUMAB2420 | ||